Dexamethasone, HELLP syndrome, and study design

American Journal of Obstetrics and Gynecology

Volumn 195, Issue 6, 2006, Pages

  O'Brien, John M ^a  

^a CENTRAL BAPTIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE;

CLINICAL TRIAL; DOSE RESPONSE; HELLP SYNDROME; HUMAN; LETTER; LOW DRUG DOSE; METHODOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HELLP SYNDROME; HUMANS; PATIENT SELECTION; PREGNANCY; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 33751215519     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.02.033     Document Type: Letter

References (3)

1. Fonseca J.E., Mendez F., Catano C., and Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 193 (2005) 1591-1598
2. O'Brien J.M., Barton J.R., and Milligan D.A. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome. Am J Obstet Gynecol 183 (2000) 921-924
3. O'Brien J.M., Schwendemann W.D., and Barton J.R. The time course response to corticosteroids in women with antepartum HELLP syndrome. Society of Maternal Fetal Medicine. Abstract (2006)